JP2018524282A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524282A5
JP2018524282A5 JP2017560324A JP2017560324A JP2018524282A5 JP 2018524282 A5 JP2018524282 A5 JP 2018524282A5 JP 2017560324 A JP2017560324 A JP 2017560324A JP 2017560324 A JP2017560324 A JP 2017560324A JP 2018524282 A5 JP2018524282 A5 JP 2018524282A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
sequence
sirp
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560324A
Other languages
English (en)
Japanese (ja)
Other versions
JP7064234B2 (ja
JP2018524282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/032921 external-priority patent/WO2016187226A1/en
Publication of JP2018524282A publication Critical patent/JP2018524282A/ja
Publication of JP2018524282A5 publication Critical patent/JP2018524282A5/ja
Priority to JP2021185050A priority Critical patent/JP2022036957A/ja
Application granted granted Critical
Publication of JP7064234B2 publication Critical patent/JP7064234B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560324A 2015-05-18 2016-05-17 Sirpポリペプチド組成物および使用の方法 Expired - Fee Related JP7064234B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021185050A JP2022036957A (ja) 2015-05-18 2021-11-12 Sirpポリペプチド組成物および使用の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562163282P 2015-05-18 2015-05-18
US62/163,282 2015-05-18
US201562266450P 2015-12-11 2015-12-11
US62/266,450 2015-12-11
PCT/US2016/032921 WO2016187226A1 (en) 2015-05-18 2016-05-17 Sirp polypeptide compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021185050A Division JP2022036957A (ja) 2015-05-18 2021-11-12 Sirpポリペプチド組成物および使用の方法

Publications (3)

Publication Number Publication Date
JP2018524282A JP2018524282A (ja) 2018-08-30
JP2018524282A5 true JP2018524282A5 (cg-RX-API-DMAC7.html) 2019-06-20
JP7064234B2 JP7064234B2 (ja) 2022-05-10

Family

ID=57320547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017560324A Expired - Fee Related JP7064234B2 (ja) 2015-05-18 2016-05-17 Sirpポリペプチド組成物および使用の方法
JP2021185050A Pending JP2022036957A (ja) 2015-05-18 2021-11-12 Sirpポリペプチド組成物および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021185050A Pending JP2022036957A (ja) 2015-05-18 2021-11-12 Sirpポリペプチド組成物および使用の方法

Country Status (10)

Country Link
US (3) US9845345B2 (cg-RX-API-DMAC7.html)
EP (2) EP3298043B8 (cg-RX-API-DMAC7.html)
JP (2) JP7064234B2 (cg-RX-API-DMAC7.html)
CN (2) CN114425077A (cg-RX-API-DMAC7.html)
CA (1) CA2994935A1 (cg-RX-API-DMAC7.html)
DK (1) DK3298043T3 (cg-RX-API-DMAC7.html)
ES (1) ES2857109T3 (cg-RX-API-DMAC7.html)
PL (1) PL3298043T3 (cg-RX-API-DMAC7.html)
PT (1) PT3298043T (cg-RX-API-DMAC7.html)
WO (1) WO2016187226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
SG10201913573UA (en) 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CA3042581A1 (en) * 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
IL268198B2 (en) 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
US11267856B2 (en) 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CN108623689B (zh) * 2017-03-15 2020-10-16 宜明昂科生物医药技术(上海)有限公司 新型重组双功能融合蛋白及其制备方法和用途
PT3625259T (pt) 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
WO2019066536A1 (ko) * 2017-09-28 2019-04-04 한국과학기술연구원 신규 암 치료용 조성물
US12110332B2 (en) 2017-11-20 2024-10-08 Taizhou Mabtech Pharmaceutical Co., Ltd. Bifunctional fusion protein targeting CD47 and PD-L1
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3085693A1 (en) * 2017-12-22 2019-06-27 Adienne S.A. Quantitative cellular method for determining the biological activity of an anti-cd26 ligand
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
IL280102B1 (en) 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
JP2022512540A (ja) 2018-08-29 2022-02-07 シャタック ラボ,インコーポレイテッド Flt3l系キメラタンパク質
JP2021534769A (ja) * 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109293778B (zh) * 2018-11-01 2021-09-17 浙江蓝盾药业有限公司 同时抗cd70和cd47的重链抗体及其制备方法和应用
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN113412279B (zh) 2018-11-15 2024-09-24 拜奥迪斯私人有限公司 人源化抗SIRPα抗体
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
EP3936526A4 (en) * 2019-03-06 2023-03-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
KR20220012328A (ko) * 2019-05-24 2022-02-03 포티 세븐, 인코포레이티드 c-kit 및 CD47에 대한 면역요법제의 병용 투여를 위한 요법
EP3980747A1 (en) * 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
MX2021015937A (es) 2019-06-24 2022-02-03 Amgen Inc Inhibicion de sirp-gamma para el tratamiento del cancer.
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
WO2021101966A1 (en) * 2019-11-18 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP2023528341A (ja) 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
WO2022048616A1 (zh) * 2020-09-04 2022-03-10 江苏恒瑞医药股份有限公司 SIRPγ变体及其融合蛋白
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR20220138909A (ko) 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CA3253030A1 (en) 2022-06-01 2023-12-07 ALX Oncology Inc. Polytherapy for the treatment of urothelial carcinoma
KR102896511B1 (ko) * 2022-09-07 2025-12-08 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체
EP4683654A1 (en) * 2023-03-22 2026-01-28 Li, Wangzhi Sirp variants and uses thereof
EP4770665A1 (en) 2023-08-31 2026-07-08 Universität Basel Vizerektorat Forschung Chimeric antigen receptor constructs and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
EP3766511A1 (en) * 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP3311824B1 (en) * 2013-02-05 2020-03-25 The Board of Trustees of the Leland Stanford Junior University Cd47 targeted therapies for the treatment of infectious disease
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse

Similar Documents

Publication Publication Date Title
CN102906112B (zh) Trail r2-特异性多聚体支架
JP7244567B2 (ja) 新規結合ドメイン含有ポリペプチドおよびその使用
CN112512581B (zh) 针对cldn18.2和cd3的抗体构建体
EP3015477B1 (en) High-stability t-cell receptor and preparation method and application thereof
JP6738314B2 (ja) Bcmaおよびcd3に対する結合分子
Weidle et al. The emerging role of new protein scaffold-based agents for treatment of cancer
CN105980406A (zh) Bcma和cd3的结合分子
CN114716557A (zh) Psma和cd3双特异性t细胞接合抗体构建体
JP2003506028A (ja) キメラポリペプチド、その製造方法、およびその使用
JP2013529070A5 (cg-RX-API-DMAC7.html)
CN107197625A (zh) 识别ny‑eso‑1抗原短肽的t细胞受体
CN108271376A (zh) 结合dll3和cd3的双特异性抗体构建体
WO2022233956A1 (en) Antigen binding proteins specifically binding prame
JP2015110619A (ja) 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
CN110776562B (zh) 一种识别afp抗原的t细胞受体
WO2010014830A2 (en) Peptide therapeutics that bind vegf and methods of use thereof
JP2021536256A (ja) 修飾t細胞に対する条件的活性型キメラ抗原受容体
CN113321727A (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
CN111100205A (zh) 靶向新型gpc3和cd19双靶点的嵌合抗原受体方法
CN108264550B (zh) 一种识别源自于prame抗原短肽的tcr
CN110577590B (zh) 一种识别afp抗原的tcr及其编码核酸
CN108948184B (zh) 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) 一种识别prame抗原短肽的tcr及其相关组合物
Xia et al. [Retracted] Development and Characterization of a Nanobody against Human T‐Cell Immunoglobulin and Mucin‐3
WO2011097633A2 (en) Egf receptor mimicking peptides